



June 15, 2015

## **Esperion Therapeutics Announces the Appointment of Scott Braunstein, M.D. to Board of Directors**

ANN ARBOR, MI -- (Marketwired) -- 06/15/15 -- Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the appointment of Scott Braunstein, M.D. as a Class III Director, with a term expiring at the 2016 annual meeting of stockholders.

"I'm very pleased to welcome Dr. Braunstein to the Esperion board," said Tim Mayleben, president and chief executive officer. "With an experience base which spans the healthcare sector -- first as a practicing physician and most recently as a successful investment manager -- Dr. Braunstein brings a wealth of knowledge and expertise to Esperion. We look forward to his insight and experienced counsel as we complete development and prepare for the commercialization of ETC-1002 for patients with uncontrolled levels of LDL-cholesterol."

Dr. Braunstein most recently served as a healthcare portfolio manager at Everpoint Asset Management. Previously, he was with J.P. Morgan Asset Management as a healthcare analyst and managing director in the U.S. Equity team and portfolio manager in the Global Healthcare team responsible for managing investments in pharmaceuticals, biotechnology and medical devices. Additional experience includes serving as the chief operating officer of STAT Medical; health care specialty sales at Deutsche Bank; and vice president of operations at Defined Healthcare. Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as Assistant Clinical Professor at Albert Einstein College of Medicine and for Columbia University Medical Center after earning his medical degree from the Albert Einstein College of Medicine.

"I am delighted to be joining Esperion's accomplished board of directors and the opportunity to support the management team as they advance ETC-1002 into Phase III development and seek to expand the treatment options available to patients with hypercholesterolemia," said Dr. Braunstein.

### ***Esperion's Commitment to Cardiometabolic Disease***

Esperion is committed to improving the lives of patients with cardiometabolic diseases. The Esperion team leverages its understanding of, and experience with, key biological pathways to discover and develop innovative therapies for the treatment of patients with hypercholesterolemia who have uncontrolled cholesterol levels despite the use of currently available therapies. Esperion has assembled a portfolio of programs including one product candidate in late-stage clinical evaluation (ETC-1002) and two preclinical product candidates.

### ***About Esperion Therapeutics***

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a first-in-class, orally available, once-daily small molecule designed to lower elevated LDL-cholesterol levels and avoid the side effects associated with currently available LDL-cholesterol lowering therapies. ETC-1002 is being developed for patients with primary hyperlipidemia and mixed dyslipidemia. For more information, please visit [www.esperion.com](http://www.esperion.com) and follow us on Twitter at <https://twitter.com/EsperionInc>.

### ***Forward-Looking Statements***

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential of, and clinical development plan for, ETC-1002. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the risk that positive results from a clinical study of ETC-1002 may not necessarily be predictive of the results of future clinical studies, particularly in different or larger patient populations, or the risk that other unanticipated developments could interfere with the development (and commercialization) of ETC-1002, as well as other risks detailed in Esperion's filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You are cautioned not to place

undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Media Contact:

Elliot Fox

W2O Group

212.257.6724

[efox@w2ogroup.com](mailto:efox@w2ogroup.com)

Investor Contact:

Mindy Lowe

Esperion Therapeutics

734.887.3903

[mloew@esperion.com](mailto:mloew@esperion.com)

Source: Esperion Therapeutics, Inc.

News Provided by Acquire Media